S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.73 HKD -2.1% Market Closed
Market Cap: 11B HKD
Have any thoughts about
SSY Group Ltd?
Write Note

SSY Group Ltd
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SSY Group Ltd
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
S
SSY Group Ltd
HKEX:2005
Common Shares Outstanding
HK$3B
CAGR 3-Years
-1%
CAGR 5-Years
0%
CAGR 10-Years
0%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Common Shares Outstanding
HK$3.5B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
6%
U
United Laboratories International Holdings Ltd
HKEX:3933
Common Shares Outstanding
ÂĄ1.8B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
1%
Sino Biopharmaceutical Ltd
HKEX:1177
Common Shares Outstanding
ÂĄ18.3B
CAGR 3-Years
-1%
CAGR 5-Years
-1%
CAGR 10-Years
5%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Common Shares Outstanding
HK$6.3B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Common Shares Outstanding
$871.4m
CAGR 3-Years
1%
CAGR 5-Years
6%
CAGR 10-Years
5%
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
11.1B HKD
Industry
Pharmaceuticals

SSY Group Ltd. is an investment holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company employs 4,800 full-time employees The company went IPO on 2005-12-20. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

Intrinsic Value
5.41 HKD
Undervaluation 31%
Intrinsic Value
Price
S

See Also

What is SSY Group Ltd's Common Shares Outstanding?
Common Shares Outstanding
3B HKD

Based on the financial report for Jun 30, 2024, SSY Group Ltd's Common Shares Outstanding amounts to 3B HKD.

What is SSY Group Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
0%

Over the last year, the Common Shares Outstanding growth was 0%. The average annual Common Shares Outstanding growth rates for SSY Group Ltd have been -1% over the past three years .

Back to Top